May 02, 2012, 07.05 PM | Source: CNBC-TV18
D D Sharma of Risk Capital Advisors is of the view that one should buy Biocon.
Sharma told CNBC-Awaaz, "One can accumulate Biocon with a stoploss of Rs 229. The stock can touch level of Rs 255 in medium term."
The company touched its 52-week high Rs 382.00 and 52-week low Rs 225.75 on 20 Jul, 2011 and 27 Apr, 2012, respectively.
Currently, it is trading -37.72% below its 52-week high and 5.38% above its 52-week low.
Speaking to CNBC-TV18 Kiran Mazumdar Shaw, CMD, Bi
"Suresh has over 30 years of experience in the pha
Biocon has informed that Suresh Subramaniam has be
Ashwani Gujral of ashwanigujral.com is of the view
The centre, named Syngene Amgen Research and Devel